Modern AI frameworks have revolutionized the detection and classification of pulmonary inflammation through advanced analysis of radiographs, CT scans, and dynamic ultrasound imaging. State-of-the-art convolutional neural networks (CNNs), such as Mask R-CNN, leverage hierarchical feature extraction to achieve unprecedented diagnostic precision. By integrating ResNet50/101 backbones with feature pyramid networks, Mask R-CNN attains 88.3% classification accuracy (95% CI 86.4-89.8) and 83.13% regression precision (intersection over union ≥0.5) in localizing pneumonia lesions on chest X-rays. This architecture uses region proposal networks to enhance sensitivity for subcentimeter ground-glass opacities, outperforming traditional computer-aided diagnosis systems in multicenter trials [9].

Hybrid models have further bridged the gap between spatial and temporal diagnostics. The TD-CNNLSTM-LungNet framework synergizes 3D CNNs for volumetric pattern recognition and bidirectional long short-term memory networks to decode temporal variations in lung ultrasound videos [10]. Evaluated on 1243 cases, this model achieved 96.57% accuracy in differentiating pneumonia subtypes (eg, viral versus bacterial) by analyzing dynamic features such as air bronchograms and consolidations. Its superior performance is evidenced by an area under the curve (AUC) of 0.983 (95% CI 0.972-0.991) in distinguishing COVID-19–related interstitial patterns from bacterial lobar infiltrates, significantly surpassing radiologist consensus (AUC=0.872, P=.003) [10].

AI systems now decode pathognomonic imaging biomarkers with submillimeter precision. For instance, VGG-Pneumonia v2.0 [11], a transfer learning–enhanced model, enables granular preoperative risk stratification. Attention mechanisms in DenseNet-121/Inception-v3 ensembles [12] have improved early detection of interstitial pneumonia to 91.4% sensitivity (κ=0.86) by mapping septal thickening patterns. Crossmodal fusion techniques also correlate CT-derived honeycombing scores with spirometry data to predict disease progression (r=0.79, P<.001) [13].

Preoperative PFTs serve as critical tools for evaluating respiratory reserve and predicting postoperative outcomes in surgical patients. Key parameters such as forced expiratory volume in 1 second (FEV₁), forced vital capacity (FVC), and diffusion capacity for carbon monoxide (DLCO) collectively offer multidimensional insights into pulmonary mechanics and gas exchange efficiency [14,15]. FEV₁ quantifies the maximum air volume forcibly exhaled within the first second, reflecting airway patency and obstructive patterns. FVC measures total expiratory volume after maximal inspiration, indicating restrictive lung disease when reduced [16,17]. The FEV₁/FVC ratio further differentiates between obstructive and restrictive pathologies, with values below 0.7 typically suggesting airflow limitation [15]. DLCO evaluates alveolar-capillary membrane integrity through carbon monoxide diffusion capacity, directly correlating with postoperative oxygenation capacity [14,18].

Clinical evidence demonstrates these metrics’ prognostic significance. In cardiac surgery populations, reduced FEV₁ (<70% predicted) and FVC (<80% predicted) independently associate with prolonged mechanical ventilation and increased pulmonary complications [14]. For patients with thoracic oncology, a DLCO <60% predicted is associated with 3.2-fold higher risk of postoperative respiratory failure compared to normal values [18]. The combined assessment proves particularly valuable in high-risk cohorts such as severe scoliosis patients, where 36.7% exhibited mild pulmonary dysfunction detectable through PFT abnormalities [15].

Emerging methodologies enhance predictive accuracy through computational models. Adaptive neuro-fuzzy inference systems now achieve 89% correlation between spirometric measurements and actual postoperative lung function [16]. Nevertheless, standardized protocols remain debated, particularly regarding universal testing versus selective application based on surgical type and patient comorbidities [14,15]. Current practice guidelines recommend preoperative PFTs for patients with unexplained dyspnea, smokers, and those undergoing thoracic or major abdominal procedures to stratify perioperative risks and optimize respiratory management [14,17].

ABG parameters—including PaO₂, partial pressure of carbon dioxide, bicarbonate, and the PaO₂/fraction of inspired oxygen ratio—serve as fundamental diagnostic biomarkers for hypoxemia and respiratory insufficiency [19]. Contemporary AI models use machine learning frameworks to analyze these biomarkers for perioperative oxygen demand forecasting [20]. As demonstrated by a multicenter, prospective cohort study, preoperative ABG trends in pH, partial pressure of carbon dioxide, and alveolar-arterial gradients can predict severe hypoxemia (PaO₂ <50 mmHg) with high accuracy. Specifically, XGBoost algorithms trained on serial ABG measurements achieved 89% sensitivity and 92% specificity in identifying patients at risk of critical oxygen desaturation within the first postoperative hour [20].

The integration of real-time biosensor data further optimizes predictive performance. Adaptive AI systems now synchronize intraoperative pulse oximetry (SpO₂) waveforms with ventilator controls, reducing hypoxemic events through dynamic intervention [21]. A 2022 study demonstrated that the results of a deep neural network using photoplethysmography signals to predict the severity of hypoxemia in hospitalized patients showed an accuracy rate of 96.5% in determining 3 severity categories, with a Cohen κ score of 0.79. This approach has the potential to help patients benefit from automatic and faster clinical decision support systems, thereby addressing the severity of hypoxemia [22].

Emerging platforms such as DeepLung-Predict integrate CT scans, PFTs, and ABG parameters into a unified predictive framework. For instance, deep lung parenchyma enhancement, a multimodal AI tool, filters out nonparenchymal CT features to accentuate inflammation-induced fibrosis while concurrently analyzing DLCO and PaO₂ to assess oxygenation capacity. In a 2024 trial, DeepLung-Predict attained an AUC of 0.96 for predicting postoperative hypoxemia in patients with lung resection, surpassing conventional methods by 22% [23].

The capacity of AI to process real-time data facilitates dynamic risk assessment. For example, recurrent neural networks undertake the analysis of intraoperative SpO₂, end-tidal carbon dioxide, and ventilator waveforms to predict hypoxemic crises several minutes prior to clinical manifestation [24]. Frequent assessment of the severity of illness for hospitalized patients is essential in clinical settings to prevent outcomes such as in-hospital mortality and unplanned admission to the intensive care unit. Classical severity scores have typically been developed using relatively few patient features. Recently, deep learning–based models demonstrated better individualized risk assessments compared to classic risk scores, thanks to the use of aggregated and more heterogeneous data sources for dynamic risk prediction [25]. 

While AI models demonstrate high accuracy in controlled settings, their real-world applicability is hindered by dataset heterogeneity. Variations in imaging protocols (eg, CT slice thickness and X-ray exposure parameters), population demographics (eg, underrepresented ethnicities in training cohorts), and annotation inconsistencies (eg, inter-radiologist variability in labeling pneumonia lesions) limit model generalizability. For instance, a 2023 study found that models trained on single-center data experienced a 15%-20% performance drop when validated on external datasets [28]. Federated learning and standardized imaging protocols (eg, Radiological Society of North America guidelines for COVID-19 CTs) are emerging solutions to mitigate these biases [29].

A 2023 meta-analysis highlighted that AI models trained on narrow datasets experience a median performance drop of 18% (95% CI 14%-22%) when applied to external cohorts, underscoring the risk of overestimating real-world efficacy [28].

The “black box” nature of deep learning models remains a barrier to clinical adoption. While attention maps in CNNs (eg, Grad-CAM visualizations [30]) partially elucidate decision-making processes, they lack granular pathophysiological correlations. Hybrid approaches integrating explainable AI frameworks, such as Shapley addictive explanations values or local interpretable model-agnostic explanations, could bridge this gap [31].

Operationalizing AI tools requires addressing infrastructural and human factors. Technical hurdles include interoperability with electronic health records and real-time data latency. Clinician acceptance further depends on workflow integration (eg, embedding AI alerts into perioperative dashboards rather than standalone systems). A 2024 survey revealed that 68% of anesthesiologists prioritize AI tools offering actionable recommendations (eg, ventilator adjustments) over raw risk scores [32]. Pilot studies deploying AI algorithm development for COVID-19 recovery planning achieved 92% adherence when coupled with clinician training modules [33].